Biocon Biologics, Viatris Inc. get CHMP nod for Abevmy, a biosimilar to Avastin

Abevmy is abiosimilar to Roche's Avastin, prescribed for all indications including metastatic colorectal carcinoma, metastatic breast cancer, non-small-cell lung carcinoma, glioblastoma, ovarian, cervical and renal cancer as part of a specific regimen, it said.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/37WAYf6
via IFTTT